840529-13-7

Basic information

• Product Name: Helioxanthin 8-1
• Synonyms: Helioxanthin 8-1;11-(1,3-Benzodioxol-5-yl)-8,9-dihydro-1,3-benzodioxolo[4,5-g]phthalazine-7,10-dione
• CAS NO: 840529-13-7
• Molecular Formula: C20H12N2O6
• Molecular Weight: 376.31908
• Mol File: 840529-13-7.mol

Chemical Properties

• Appearance: /
• Solubility: Soluble in DMSO
• CAS DataBase Reference: Helioxanthin 8-1(CAS DataBase Reference)
• NIST Chemistry Reference: Helioxanthin 8-1(840529-13-7)
• EPA Substance Registry System: Helioxanthin 8-1(840529-13-7)

Safety Data

• Hazardous Substances Data: 840529-13-7(Hazardous Substances Data)

Usage

Biological Activity

helioxanthin 8-1, an analogue of helioxanthin (ach126447), is an inhibitor of hbv and hiv virus with ec50 values of 0.03 μm and 2.7 μm, respectively [1].helioxanthin 8-1 is the cyclic hydrazide derivative of helioxanthin and has shown significant in vitro antivirus activity with ec50 values of 0.03 μm and 2.7 μm for hbv and hiv, respectively [1]. in the ds-tet5 cells, helioxanthin 8-1 can inhibit duck hepatitis b virus (dhbv) dna synthesis with a mean ic50 value of 0.25±0.05 μm. besides, in induced cells and non-induced ds-tet5 cells, helioxanthin 8-1 has cytotoxic effect with cc50 values of 18±2 μm and 45±3 μm, respectively, by using an mtt assay [2].

references

[1] yeo h1, li y, fu l, zhu jl, gullen ea, dutschman ge, lee y, chung r, huang es, austin dj, cheng yc. synthesis and antiviral activity of helioxanthin analogues. j med chem. 2005 jan 27;48(2):534-46.[2] ying c1, tan s, cheng yc. helioxanthin analogue 8-1 inhibits duck hepatitis b virus replication in cell culture. antivir chem chemother. 2010;21(2):97-103.

Upstream product

• 175883-70-2 10-benzo[1,3]dioxol-5-yl-furo[3',4':6,7]naphtho[1,2-d][1,3]dioxole-7,9-dione 
• 175883-69-9 Benzo[1,3]dioxol-5-yl-(5-[1,3]dioxolan-2-yl-benzo[1,3]dioxol-4-yl)-methanol 
• 4405-18-9 5-[1,3]dioxolan-2-yl-benzo[1,3]dioxole 
• 120-57-0 piperonal 
• 840529-10-4 N-(10-benzo[1,3]dioxol-5-yl-7,9-dioxo-7,9-dihydro1,3-dioxa-8-aza-dicyclopenta[a,g]naphthalen-8-yl)-acetamide 

Relevant articles and documents

NOVEL ANTIVIRAL HELIOXANTHIN ANALOGS

The present invention relates to novel antiviral helioxanthin analogs. These compounds may particularly be used alone or in combination with other drugs for the treatment of the following: hepadnaviruses, flaviviruses, herpesviruses and human immunodefici

Synthesis and antiviral activity of helioxanthin analogues

A series of natural product analogues based on helioxanthin (2), with particular attention to modification of the lactone ring and methylenedioxy group, were synthesized and evaluated for their antiviral activities. Among them, lactam derivative 18 and helioxanthin cyclic hydrazide 28 exhibited significant in vitro antiviral activity against hepatitis B virus (EC 50 = 0.08 and 0.03 μM, respectively). Compound 18 showed the most potent antiviral activity against hepatitis C virus (55% inhibition at 1.0 μM). Compound 12, an acid-hydrolyzed product of helioxanthin cyclic imide derivative 9, was found to exhibit broad-spectrum antiviral activity against hepatitis B virus (EC50 = 0.8 μM), herpes simplex virus type 1 (EC50 = 0.15 μM) and type 2 (EC50 50 = 9.0 μM), and cytomegalovirus (EC 50 = 0.45 μM). Helioxanthin lactam derivative 18 also showed marked inhibition of herpes simplex virus type 1 (EC50 = 0.29 μM) and type 2 (EC50 = 0.16 μM). The cyclic hydrazide derivative of helioxanthin 28 and its brominated product 42 exhibited moderately potent activities against human immunodeficiency virus (EC50 = 2.7 and 2.5 μM, respectively). Collectively, these molecules represent a novel set of antiviral compounds with unique structural features.